Publication Recommends OGM for Analysis of Hematological Neoplasms Due to Streamlined Structural Variant Detection and High Concordance with Traditional Cytogenetic Methods
November 03 2022 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the first
published validation study to evaluate the performance of optical
genome mapping (OGM) versus traditional cytogenetic techniques for
the analysis of hematological neoplasms. According to the study,
when compared to traditional cytogenetic methods, OGM showed robust
technical and analytical performance, corrected misinterpretations
and resolved balanced and unbalanced variants with high resolution
in a single assay, streamlining the existing need to run multiple
platforms.
Researchers analyzed samples from 69 individuals referred to a
clinical lab for cytogenetic analysis to assess OGM as an approach
to provide cytogenetic profiling in hematological
neoplasms that included acute myeloid leukemia (AML), chronic
myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL).
OGM’s technical performance resulted in a 100% first-pass rate,
with concordance to traditional methods showing a sensitivity of
98.7%, a specificity of 100%, and an accuracy of 99.2%. OGM
identified several additional structural variants (SVs) not
detected by other methods, revealing the genomic architecture in
these neoplasms that the study authors believe may provide an
opportunity for better tumor classification, prognostication,
risk-stratification, and therapy selection.
Erik Holmlin, PhD, president and chief executive officer of
Bionano commented, “We are gratified to see study results showing
how OGM may be useful in the analysis of hematological neoplasms.
We believe that the study findings show OGM may alleviate the need
for multiple technologies, and that it has potential to become a
first tier cytogenomic test for hematologic malignancies.”
This publication can be found here:
https://www.jmdjournal.org/article/S1525-1578(22)00290-2/fulltext
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides diagnostic testing
for patients with clinical presentations consistent with autism
spectrum disorder and other neurodevelopmental disabilities.
Through its BioDiscovery business, the Company also offers an
industry-leading, platform-agnostic software solution, which
integrates next-generation sequencing and microarray data designed
to provide analysis, visualization, interpretation and reporting of
copy number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. For more
information, visit www.bionanogenomics.com,
www.bionanolaboratories.com or www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “believe,” “potential,” “may,” “believe” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) convey
uncertainty of future events or outcomes and are intended to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the utility of OGM to provide cytogenetic
profiling in hematological neoplasms that included acute
myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). Each
of these forward-looking statements involves risks and
uncertainties. Actual results or developments may differ materially
from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: the impact of the COVID-19
pandemic on our business and the global economy; general market
conditions; changes in the competitive landscape and the
introduction of competitive technologies or improvements to
existing technologies; failure of OGM to be adopted as a tool for
cytogenetic profiling in hematological neoplasms that included
acute myeloid leukemia (AML) and chronic lymphocytic leukemia
(CLL); future study results contradicting the results reported in
the publication referenced above; changes in our strategic and
commercial plans; our ability to obtain sufficient financing to
fund our strategic plans and commercialization efforts; the ability
of medical and research institutions to obtain funding to support
adoption or continued use of our technologies; and the risks and
uncertainties associated with our business and financial condition
in general, including the risks and uncertainties described in our
filings with the Securities and Exchange Commission, including,
without limitation, our Annual Report on Form 10-K for the year
ended December 31, 2021 and in other filings subsequently made by
us with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Sep 2023 to Sep 2024